Pentagamavunon-0 is a modified curcumin compound inhibiting cancer cells. Now the developed chitosan nanoparticles to carry curcumin is more effective to inhibit cancer cells. This drug is a modified curcumin. Modification of this drug is a combination of curcumin in the overlying chitosan nanoparticle size.
PGV-0 is a derivative analog of curcumin derived from turmeric and ginger rhizome. PGV-0 patented in the U.S. with Patent No. US-6777. 447B2. PGV-0 proved to have the ability to inhibit the enzyme cyclooxygenase (COX-2) are found in cancer cells. Expression of COX-2 enzyme tends to increase in the cancer cells so it must be inhibited for the healing process.
PGV-0 as anticancer drugs also have drawbacks in the form dissolved in water level is low so it needs to be combined with chitosan dissolved in water with a high. Anticancer drugs with nanoparticle technology is pursued through the encapsulation of curcumin with 2-5 nanometer-sized chitosan. Availability of raw materials for curcumin and chitosan thus likely to be abundant cheap drugs.